The effect of enfuvirtide (ENF) in 11 HIV-1 heavily antiretroviral-experienced children and adolescents enrolled in the HIV-1 Paediatric Spanish cohort was further investigated. Patients who received ENF with novel drugs (etravirine, darunavir, and/or tipranavir) reached and maintained undetectable plasma HIV-1 RNA levels and showed immunological recovery within the first 3 months of therapy that was maintained during the follow-up. Viremia was not fully suppressed in patients who did not combine ENF with novel drugs but interestingly, immunological benefit was observed in half of these patients. Therefore, ENF showed a greater and more stable efficacy when administrated with novel drugs.
Get full access to this article
View all access options for this article.
References
1.
LalezariJP, HenryK, O'HearnMet al.Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med, 2003; 348:2175–2185.
2.
LazzarinA, ClotetB, CooperDet al.Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med, 2003; 348:2186–2195.
3.
BattegayM, DeMasiR, DelehantyJet al.Analysis of virological failure through 24 weeks of treatment in the TORO pivotal studies. Antivir Ther, 2003; 8,Suppl. 1.
4.
HolguinA, FaudonJL, LabernardiereJLet al.Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide. J Clin Virol, 2007; 38:176–180.
5.
ChurchJA, HughesM, ChenJet al.Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J, 2004; 23:713–718.
6.
BellibasSE, SiddiqueZ, DorrAet al.Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J, 2004; 23:1137–1141.
7.
Garcia-MerinoI, de Las CuevasN, JimenezJLet al.The Spanish HIV BioBank: A model of cooperative HIV research. Retrovirology, 2009; 6:27.
8.
SharlandM, BlancheS, CastelliGet al.PENTA guidelines for the use of antiretroviral therapy. HIV Med, 2004; 5,Suppl 2:61–86.
9.
WizniaA, ChurchJ, EmmanuelPet al.Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J, 2007; 26:799–805.
10.
ReddingtonC, CohenJ, BaldilloAet al.Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J, 2000; 19:1148–1153.
